| Literature DB >> 32803699 |
Yuki Fujiwara1, Ken-Ichi Matsuoka2, Miki Iwamoto1, Yuichi Sumii1, Masaya Abe1, Kentaro Mizuhara1, Tomohiro Urata1, Kyosuke Saeki1, Yusuke Meguri1, Noboru Asada1, Daisuke Ennishi1, Hisakazu Nishimori1, Keiko Fujii1, Nobuharu Fujii1, Junichi Sugita3, Hajime Kobayashi4, Takahiro Oto5, Yoshinobu Maeda1.
Abstract
Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.Entities:
Keywords: Allogeneic hematopoietic stem cell transplantation; Lung transplant; Myelodysplastic syndromes; Transplant tolerance
Mesh:
Year: 2020 PMID: 32803699 DOI: 10.1007/s12185-020-02967-x
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490